JAZZ Q1 Deep Dive: Oncology and Neuroscience Drive Double-Digit Revenue Growth, Eyes on Upcoming Approvals

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 19.1% year on year to $1.07 billion. On the other hand, the company’s full-year revenue guidance of $4.38 billion at the midpoint came in 1.7% below analysts’ estimates. Its non-GAAP profit of $6.34 per share was 36.2% above analysts’ consensus estimates.

Is now the time to buy JAZZ? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Jazz Pharmaceuticals delivered a first quarter that was met with a positive response from the market, driven largely by strong commercial execution across its sleep, epilepsy, and oncology franchises. Management credited the performance to robust demand for Xywav, Epidiolex, Midevo, and Zepzelca, with CEO Renée Galá highlighting, “Our commercial teams generated double-digit growth across all our promoted brands, and saw strong contributions from our ongoing launches.” The company’s focus on differentiated patient support and broadening market penetration for both new and established therapies contributed to the notable revenue growth observed this quarter.

Looking ahead, Jazz Pharmaceuticals' outlook is centered on pipeline progress and several anticipated regulatory milestones. Management underscored preparations for the potential FDA approval and launch of ZYHERA for HER2-positive gastric cancer, describing it as a significant opportunity given the unmet medical need. CFO Philip Johnson noted, “Our full-year guidance reflects expectations for increased competition in the sleep franchise and evolving payer dynamics.” Efforts to expand the reach of Epidiolex in adult and international populations, along with investment in additional rare disease indications and business development, are expected to shape the company’s performance for the remainder of the year.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to the continued uptake of key products in sleep, epilepsy, and oncology, as well as early momentum from recent launches and pipeline advancement.

• Xywav momentum in sleep disorders: Xywav saw continued expansion in narcolepsy and idiopathic hypersomnia (IH), driven by physician and patient education efforts, plus a strong patient support infrastructure. Management emphasized the differentiation of Xywav as the only low-sodium option, with net patient adds remaining robust despite the entry of high-sodium generics and new wake-promoting agents.
• Epidiolex growth in new segments: Epidiolex achieved 15% sales growth, attributed to increasing adoption in adult and long-term care settings. Jazz Pharmaceuticals is investing in diagnostic tools and a nurse navigator program to drive persistency and uptake, particularly as the product’s international presence grows via partnerships like the one in Japan with Nippon Zoki.
• Midevo launch addresses unmet need: Midevo’s initial sales reflect strong physician engagement and high patient demand in diffuse midline glioma. Management pointed to rapid adoption and longer-than-expected treatment duration, and noted the ACTION trial may further expand its use into first-line therapy.
• ZYHERA pre-launch positioning: Jazz Pharmaceuticals is preparing for a potential launch of ZYHERA in HER2-positive gastric cancer, benefiting from FDA priority review. The company’s cross-functional teams are focused on rapid adoption post-approval, leveraging established relationships in overlapping solid tumor accounts and anticipating favorable payer access due to compelling clinical trial outcomes.
• Strong oncology portfolio performance: Zepzelca reported accelerated growth following frontline maintenance approval in combination with Tecentriq, with frontline adoption offsetting declines in second-line usage. Management noted that ongoing investments in evidence generation and support services are key to sustaining this momentum, even as competitive dynamics evolve.

Drivers of Future Performance

Management’s outlook for the rest of the year centers on product lifecycle management, pipeline execution, and the ability to navigate rising competition in core franchises.

• Competitive pressures in sleep: Jazz Pharmaceuticals anticipates increased volume from high-sodium generics and new wake-promoting agents in the narcolepsy market during the second half of the year. Management expects these dynamics to gradually impact Xyrem and authorized generic volumes, but believes Xywav’s unique positioning and strong payer coverage will support continued leadership in low-sodium oxybates and IH treatment.
• Pipeline and regulatory milestones: The company is focused on potential FDA approval and launch of ZYHERA for gastric cancer, as well as interim data readouts from pivotal trials for zanidatumab in breast cancer and Midevo in the ACTION study. Success in these programs could meaningfully expand addressable patient populations and diversify the revenue base.
• Business development and portfolio expansion: Management highlighted ongoing efforts to pursue licensing, mergers, and acquisitions in rare disease, with a clear strategy to build on current strengths in sleep, epilepsy, and oncology. The company’s financial flexibility is expected to support both internal R&D and external growth initiatives, though execution risk remains as competitive and payer landscapes evolve.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will monitor (1) the timing and outcome of the FDA's decision on ZYHERA for gastric cancer, (2) interim and top-line readouts from pivotal studies for Midevo and zanidatumab, and (3) the competitive landscape’s impact on the sleep franchise as generics and new therapies increase their market presence. Continued execution in business development and the ability to expand into new rare disease areas will also be key indicators of progress.

Jazz Pharmaceuticals currently trades at $222.00, up from $212.26 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.